An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
Bavarian Nordic
ClinicalTrials.gov Identifier:
NCT00686582
First received: May 27, 2008
Last updated: May 21, 2010
Last verified: May 2010

May 27, 2008
May 21, 2010
August 2008
July 2009   (final data collection date for primary outcome measure)
Percentage of subjects with appearance (initially seronegative subjects) or increase (compared to baseline by pre-existing titers) of antibody titers in a vaccinia-specific IgG ELISA derived from individual peak responses. [ Time Frame: 7 months ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00686582 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees
An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees

The objective of the current study is to show that the immune response of subjects previously vaccinated with one or two doses of IMVAMUNE® can be boosted two years later with one IMVAMUNE® vaccination. Assessment of individual antibody titers within short time intervals following the booster vaccination will provide information on how fast and effective measurable antibody titers can be reactivated.

In summary, this study is intended to confirm that a single dose of IMVAMUNE® can reactivate antibody titers in subjects after being primed with one or two doses of IMVAMUNE®.

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Smallpox
  • Biological: IMVAMUNE
    1x 10E8_TCID50
  • Procedure: Blood Draw Only
  • Experimental: Group 1
    Intervention: Biological: IMVAMUNE
  • Experimental: Group 2
    Intervention: Biological: IMVAMUNE
  • Group 4
    Intervention: Procedure: Blood Draw Only
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
304
October 2009
July 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

Groups 1 and 2 (first consenting 75 subjects in each group to be vaccinated)

  • Male and female subjects having participated in Group 1 or 2 of the study POX-MVA-005 who completed the trial according to protocol.
  • Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine or serum pregnancy test within 24 hours prior to vaccination.
  • Women of childbearing potential must have used an acceptable method of contraception for 30 days prior to the vaccination, must agree to use an acceptable method of contraception during the study, and must not become pregnant for at least 28 days after the vaccination. A woman is considered of childbearing potential unless post-menopausal or surgically sterilized. (Acceptable contraception methods are restricted to abstinence, barrier contraceptives, intrauterine contraceptive devices or licensed hormonal products.)
  • Read, signed and dated informed consent document after being advised of the risks and benefits of the study in a language understood by the subject signed, and prior to performance of any study specific procedure.
  • Troponin I within normal institutional limits.
  • White blood cells ≥ 2,500/mm3 and <= 11,000/mm3.
  • Absolute neutrophil count within normal limits.
  • Negative urine glucose by dipstick or urinalysis.
  • Hemoglobin within the laboratory reference ranges (unless the investigator considers the deviation to be not clinically significant).
  • Platelets 100 - 440/nL.
  • Adequate renal function defined as:

    1. Serum creatinine without clinically significant findings.
    2. Urine protein <= 30 mg/dL or none or trace proteinuria (by urinalysis or dip stick).
  • Adequate hepatic function defined as:

    1. Total bilirubin <= 1.5 x upper limit of normal (ULN) in the absence of other evidence of significant liver disease (healthy subjects without clinical disease; Morbus Meulengracht can be included).
    2. AST (SGOT), ALT (SGPT), alkaline phosphatase without clinically significant findings.
  • Electrocardiogram (ECG) without clinically relevant abnormal findings (e.g. any kind of atrioventricular or intraventricular conditions or blocks such as complete left or right bundle branch block, AV node block, QTc or PR prolongation, premature atrial contractions or other atrial arrhythmia, sustained ventricular arrhythmia, two premature ventricular contractions (PVC) in a row, ST elevation consistent with ischemia).

Group 4 (all subjects) and Groups 1 and 2 (subjects N > 75): blood draw only

  • Male and female subjects having participated in the study POX-MVA-005 who completed the trial according to protocol.
  • Read, signed and dated informed consent document after being advised of the risks and benefits of the blood draw in a language understood by the subject signed, and prior to performance of the blood draw.

Exclusion Criteria:

Groups 1 and 2 (first consenting 75 subjects in each group to be vaccinated)

  • Participation in another study with a smallpox vaccine after the POX-MVA-005 study.
  • Pregnant or breast-feeding women.
  • Uncontrolled serious infection i.e. not responding to antimicrobial therapy.
  • History of any serious medical condition, which in the opinion of the investigator would compromise the safety of the subject.
  • History of or active autoimmune disease. Persons with vitiligo or thyroid disease taking thyroid replacement are not excluded.
  • Known or suspected impairment of immunologic function including, but not limited to, clinically significant liver disease; diabetes mellitus; moderate to severe kidney impairment.
  • History of malignancy, other than squamous cell or basal cell skin cancer, unless there has been surgical excision that is considered to have achieved cure. Subjects with history of skin cancer must not be vaccinated at the previous site of cancer.
  • History or clinical manifestation of clinically significant and severe hematological, renal, hepatic, pulmonary, central nervous, cardiovascular or gastrointestinal disorders.
  • Clinically significant mental disorder not adequately controlled by medical treatment.
  • Any condition which might interfere with study objectives or would limit the subject's ability to complete the study or to be compliant in the opinion of the investigator.
  • History of coronary heart disease, myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or transient ischemic attack, uncontrolled high blood pressure, or any other heart condition under the care of a doctor.
  • History of an immediate family member (father, mother, brother, or sister) who died due to ischemic heart disease before age 50 years.
  • Twenty percent or greater risk of developing a myocardial infarction or coronary death within the next 10 years using the National Cholesterol Education Program's risk assessment tool. (http://hin.nhlbi.nih.gov/atpiii/calculator.asp?usertype=prof).
  • History of intravenous drug abuse.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. tris (hydroxymethyl)-amino methane, chicken embryo fibroblast proteins, aminoglycosides (gentamycin).
  • History of any anaphylactic shock or severe allergic reaction requiring immediate treatment.
  • Having received any vaccinations or planned vaccinations with a live vaccine within 30 days prior or after study vaccination.
  • Having received any vaccinations or planned vaccinations with a killed vaccine within 14 days prior or after study vaccination.
  • Chronic administration (defined as more than 14 days) of > 5 mg prednisone (or equivalent) per day or any other immune-modifying drugs during a period starting from three months prior to administration of the vaccine and ending at study conclusion (Visit 4).
  • Post organ transplant subjects whether or not receiving chronic immunosuppressive therapy.
  • Administration or planned administration of immunoglobulins and/or any blood products during a period starting from 3 months prior to administration of the vaccine and ending at study conclusion.
  • Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding administration of the study vaccine, or planned administration of such a drug during the study period.

Group 4 (all subjects) and Groups 1 and 2 (subjects N > 75): blood draw only

  • Participation in another study with a smallpox vaccine after the POX-MVA-005 study.
  • Any condition which might interfere with a blood draw.
Both
18 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT00686582
POX-MVA-023, EudraCT-No.2007-006297-28, DMID 08-0018
Yes
Monika Fluer, Bavarian Nordic
Bavarian Nordic
National Institute of Allergy and Infectious Diseases (NIAID)
Not Provided
Bavarian Nordic
May 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP